Cassava Sciences ( (SAVA) ) has provided an announcement.
Rick Barry, CEO of Cassava Sciences, updated the community on the company’s progress, particularly regarding the ReTHINK Phase 3 clinical trial for Alzheimer’s, which has completed patient dosing and is awaiting data analysis. Notably, the ReTHINK and upcoming ReFOCUS trials are independent of each other, enhancing the credibility of their results. Amid these advancements, Cassava settled with the SEC, paying a $40 million penalty for inaccurately disclosed information, allowing the company to concentrate on simufilam’s development. Despite setbacks, Cassava remains committed to improving corporate governance and is optimistic about providing an effective Alzheimer’s treatment.
See more data about SAVA stock on TipRanks’ Stock Analysis page.
